| |
|
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Alzheimer
Patient-research |
|
Sunset Redfish Bay Fort
Myers, Florida photo by
Marty L. Hinz, MD |
|
|
|
Alzheimer
Patient-research |
 |
|
|
Contact us or find
a caregiver using this approach. |
|
|
Alzheimer
Patient |
|
Written by:
Marty L. Hinz, MD |
|
President
Clinical
Research |
|
NeuroResearch
Clinics,
Inc. |
|
|
Cape Coral,
Florida USA
Research
Office |
|
|
|
|
Real treatment for the Alzheimer Patient, where
brain function is
truly restored and
disease is controlled, has eluded medicine. The NeuroResearch Clinics approach to
Alzheimer
Patient Treatment produces excellent
results.
Alzheimer
Patient
The NeuroResearch
Clinics approach to
treatment of the
Alzheimer Patient
involves
neurotransmitter
optimization of the
master
neurotransmitters of
the brain serotonin,
dopamine,
norepinephrine and
epinephrine. These
neurotransmitters
directly and
indirectly control
virtually every
function in the
brain and body.
NeuroResearch
Clinics uses 5-HTP,
tyrosine, levodopa,
and cysteine guided
by neurotransmitter testing as indicted
to restore brain
function and get
other symptoms under
control in
the
Alzheimer
Patient. For
the
Alzheimer
Patient under going
treatment
most show
significant improvement of
cognitive brain
function. 15%
to 20% of Alzheimer
Patients
undergoing treatment
achieve profound
restoration of
brain function.
Please, read the
case studies in the
right brown colored
column, these were
written by medical
doctors (MDs) based
on medical care
experiences. With
restoration of the
brain in the
Alzheimer Patient
is
aimed at
neurotransmitter
optimization is in a
league of its own,
beyond results seen
with any
prescription drug in
the past.
Its no secret, NeuroResearch Clinics uses the nutrients 5-HTP, tyrosine, levodopa,
and cysteine to treat medical
patients in order to get these
results. Proper
use of these simple ingredients in
medical treatment is not simple.
From time to time a patient will
say, "Why do I want to take that, I
can go to a health food store and
buy it?" People off the street
buying in a health food store is
like going to an art store and
buying a bunch of oil paints then
going home and expecting to paint
like a mater artist even though
there was no previous painting
experience. These nutrients have
tremendous potential due to their
chemical properties. This potential
is only fully realized in the hands
of the trained professional using
neurotransmitter testing. Treatment
is not just giving a nutrient pill, it is the whole medical management approach doctors are trained in to insure that that treatment is on track in order to get symptoms under control. |
|
|
|
Alzheimer
Patient
SYMPTOMS
While deterioration of
brain function takes
the spot light in
the
Alzheimer
Patient
there are many
other problems that
can be active,
including:
-
Sleep
patterns,
Many
Patient
suffer
from
abnormal
sleep
patterns,
up
during
the
night
wandering
around
or
sleeping
during
the day.
With
serotonin
and
dopamine
optimization
treatment
normal
sleep
patterns
are
restored
in the
Patient.
-
Inappropriate
anger,
aggression,
or
yelling
out,
is a
problem
with some
Patient.
With
serotonin
and
dopamine
optimization
treatment inappropriate
anger,
aggression,
or
yelling
out are
controlled
in the
patient.
-
Agitation,
many
Patient
suffer
from
inappropriate
agitation.
This may
take the
form of
mental
or
physical
agitation.
With
serotonin
and
dopamine
optimization
treatment agitation
is
controlled
in the patient.
-
Depression
is
common
in
Patient.
Depression may
display
as an
agitated
depression.
In
medicine
there is
no drug that
effectively
controls
depression
in the
elderly, with
or
without
Alzheimer.
With
neurotransmitter
optimization
treatment of serotonin
and
dopamine
guided
by
neurotransmitter testing
when
indicated
depression
is
controlled.
-
Anxiety, may be present.
With
neurotransmitter
optimization
treatment of serotonin
and
dopamine
guided
by
neurotransmitter testing
as
indicted, anxiety
in the
Alzheimer
patient
may be
controlled.
-
Psychotic state is a significant problem with
Patient talking
about
and hearing or
seeing
things
that are
not
there.
With
neurotransmitter
optimization
treatment of serotonin
and
dopamine
guided
by
neurotransmitter testing
as
indicated,
the
Alzheimer
patient
may
experience
control
of
inappropriate
perceptions.
-
Restless
Leg
Syndrome
is
common,
contributing
greatly
sleep
disturbance
which
leads to
exacerbation
of
cognitive
problems.
With
neurotransmitter
optimization
treatment of
serotonin
and
dopamine
guided
by
neurotransmitter testing
as
indicted,
Restless
Leg
Syndrome
in the
Alzheimer
patient
can be
controlled.
The Peer Reviewed Research
of NeuroResearch Clinics
The neurotransmitter treatment research findings of NeuroResearch Clinics
have not been ignored. The University of
Minnesota Medical School is writing a series of
papers on the neurotransmitter testing research of NeuroResearch Clinics. The first of a series of papers by University of Minnesota Medical School based on the neurotransmitter testing research of NeuroResearch was published in "NeuroPsychiatric Disease and Treatment" May 1, 2009. Ingrid
Kohlstadt, MD of Johns Hopkins in her new
medical text book released February 7, 2009
included a chapter on depression written by
Marty L. Hinz, MD President Clinical
Research NeuroResearch Clinics outlining in
depth the proper use of amino acids and
neurotransmitter testing in treatment of
depression.
Alzheimer
Patient |
|
|
WHAT CAUSES
Alzheimer?
Elevation of
neurotransmitter
levels,
guided by
neurotransmitter testing,
reveals
excellent
results in
Alzheimer
treatment.
Review of
neurotransmitter testing
prior to
Care
reveals that
Patient
with
Alzheimer,
as a group,
have
virtually
the same
neurotransmitter
levels as
those that
do not.
Therefore
low levels
of
neurotransmitters
are not the
cause of
Alzheimer.
The primary
cause of
Alzheimer appears
to be brain
damage. The
leading
cause is
neurotoxic
damage. Just
as with
Parkinson's
Care Patient
elevating
neurotransmitter
levels
restores
flow of
electricity
in the brain
compensating
for brain
damage,
restoring
normal
function,
and
relieving
symptoms.
Alzheimer
Patient
Links
Alzheimer
Patient
organization
Alzheimer
Patient
Medline
Alzheimer
Patient
Mayo
Alzheimer
Patient
Foundation
Alzheimer
Patient
news
|
|
|
